Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours

Abstract

Immunohistochemical localization of epidermal growth factor receptor (EGFR) in normal salivary glands and tumours (108 cases) was studied using a monoclonal antibody. In the normal salivary glands, EGFR was occasionally detected in ductal segments of intercalated, striated, and excretory ducts, but not in acinar cells. The frequency of positive EGFR staining in salivary gland tumours was not high: pleomorphic adenoma, 33.8%; mucoepidermoid tumour, 25.0%; adenolymphoma, 44.4%; and sialoadenocarcinoma, 66.6%. Pleomorphic adenomas showed positive staining for EGFR on the luminal side of luminal cells and in squamous metaplastic cells of tumour tissue. Some modified myoepithelial cells were also reactive whereas outer spindle tumour cells were unstained. Adenolymphomas regularly exhibited positive EGFR staining in the cell membrane; mucoepidermoid carcinoma displayed positive staining in cell membranes in epidermoid tumour cells and cytoplasmic staining in mucous-secreting tumour cells. Sialocarcinomas revealed cell membrane staining and whole cytoplasmic staining for EGFR. The immunohistochemical localization of EGFR could be classified into two types, one the cell membrane-positive type found in epithelial tumour cells, and the second the cytoplasmic positive type seen in normal ductal cells, the luminal tumour cells of pleomorphic adenomas and mucous-secreting tumour cells.

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

“…A high frequency of EGFR overexpression has been reported in head and neck cancers (31). The overexpression of EGFR is generally believed to be common in salivary gland carcinoma, although the incidence of positive EGFR staining was found to be 25% (2/8) in an earlier study with a small sample size (20). Gibbons et al found 17 out of 22 (77%) mucoepidermoid carcinoma cases with EGFR overexpression (21).…”

“…According to the limited literature, the overexpression of EGFR was reported to be 25 and 77% respectively (20,21). EGFR-targeted drugs are now commercially available, including small-molecule tyrosine kinase inhibitors (e.g.…”

“…The knowledge of EGFR levels within mucoepidermoid carcinoma was limited and the reported frequencies of EGFR overexpression varied greatly (20,21). HER2 overexpression occurs in 0 to 38% of mucoepidermoid carcinoma (22)(23)(24)(25)(26)(27)(28).…”

Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study

“…Neuroendocrine tumors of the lung, including small cell carcinomas, usually do not express EGFR 13 and are virtually always negative for EGFR mutation. 14 Although EGFR expression has been reported in salivary gland carcinomas of the head and neck, [15][16][17][18] little is known about EGFR mutation, amplification, and expression in salivary gland-type tumors of the lung.…”

Yumuşak dokunun nadir görülen tümörlerinde ve odontojenik tümörlerde immünohistokimyasal yöntem ve floresan in situ hibridizasyonla epidermal growth faktör reseptör varlığının gösterilmesi

“…Among 17 patients in whom the immunohistochemical method showed a negative result, low-level amplification was found in three, disomy was found in nine and evaluation could not be made in four, since the tissue was shed ( showed EGFR positivity in non-small cell carcinomas of the lung8. EGFR has also been investigated in breast cancer, malign gliomas, salivary gland tumors, gastric carcinomas and bladder tumors [9][10][11][12][13] . In the literature, EGFR has also been investigated in non-neoplasic/benign lesions.…”